RxDoctor Payments Data

Cassandra Mueller

Acute Care · Lincoln, NENPI 1407538093

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Boston Scientific at 25.0% of the total.

$613in general payments, 2019–2025

Across 31 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$153
  • Medtronic$59
  • Bridgebio Pharma, Inc.$51
  • Pfizer$49
  • E.r. Squibb & Sons, L.L.C.$48
  • Novo Nordisk$47
  • plus $206 from 9 others

What the payments were for

  • Food & beverage$59597%
  • Education$183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$613 in reported general payments places this provider in the 65th percentile of 103 acute care providers in Nebraska.

See all acute care providers in Nebraska

Medicare billing

Part B allowed, 2024
$31,652
Medicare patients
309
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$95,108
XareltoRivaroxaban34$37,163
Repatha SureclickEvolocumab26$17,817
JardianceEmpagliflozin19$12,145
Metoprolol Succinate93$1,731
Amiodarone Hcl52$1,279
SotalolSotalol Hcl45$1,268
ClopidogrelClopidogrel Bisulfate75$908
Flecainide Acetate24$716
Pantoprazole Sodium55$624
Nebivolol Hcl13$484
Rosuvastatin Calcium23$394
Atorvastatin Calcium32$347
Potassium Chloride18$329
Carvedilol40$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$49$95,108104 claims
Johnson & JohnsonXarelto$16$37,16334 claims
Boehringer IngelheimJardiance$21$12,14519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 103 acute care providers in Nebraska.

Other acute care in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →